Precirix Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $89M

  • Investors
  • 11

Precirix General Information

Description

Developer of radio-immunotherapeutic drugs designed to offer a new generation of targeted cancer therapies. The company's drugs are based on the camelid immune system which uses antigen-binding fragments to transport therapeutic radioisotopes to selected target receptors on the cancer cell surface, enabling patients to receive personalized cancer medicine.

Contact Information

Formerly Known As
Camel-IDS
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Burgemeester Etienne Demunterlaan 3
  • 1090 Brussels
  • Belgium
+32 02
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Burgemeester Etienne Demunterlaan 3
  • 1090 Brussels
  • Belgium
+32 02

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precirix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 16-Mar-2022 $89M Completed Clinical Trials - Phase 2
7. Grant 01-Jan-2019 Completed Clinical Trials - Phase 1
6. Early Stage VC (Series A) 16-Nov-2018 Completed Clinical Trials - Phase 1
5. Early Stage VC 24-Oct-2017 Completed Startup
4. Grant 01-Dec-2015 Completed Startup
3. Grant 01-Dec-2014 Completed Startup
2. Capitalization 01-Oct-2014 $79.1K $79.1K Completed Startup
1. University Spin-Out 01-Jan-2014 Completed Startup
To view Precirix’s complete valuation and funding history, request access »

Precirix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference B Shares
Preference A Shares
Ordinary 15,000 $110.83 $110.83 1x $110.83 5.11%
To view Precirix’s complete cap table history, request access »

Precirix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of radio-immunotherapeutic drugs designed to offer a new generation of targeted cancer therapies. The company'
Biotechnology
Brussels, Belgium
43 As of 2023

Santa Monica, CA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Precirix Competitors (33)

One of Precirix’s 33 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA
Genprex Formerly VC-backed Austin, TX
Light Chain Bioscience Private Equity-Backed Geneva, Switzerland
Loxo Oncology Formerly VC-backed Stamford, CT
Aileron Therapeutics Formerly VC-backed Watertown, MA
You’re viewing 5 of 33 competitors. Get the full list »

Precirix Patents

Precirix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3192297-A1 Reactions of radioactive compounds facilitated by a solid phase Pending 11-Sep-2020
EP-3967674-A1 Reactions of radioactive compounds facilitated by a solid phase Pending 11-Sep-2020
AU-2021340192-A1 Reactions of radioactive compounds facilitated by a solid phase Pending 11-Sep-2020
EP-4211099-A1 Reactions of radioactive compounds facilitated by a solid phase Pending 11-Sep-2020
US-20230382855-A1 Reactions of radioactive compounds facilitated by a solid phase Pending 11-Sep-2020 C07D207/46
To view Precirix’s complete patent history, request access »

Precirix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Precirix Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Forbion Venture Capital Minority
Inkef Venture Capital Minority
Jeito Growth/Expansion Minority
BioMedPartners Venture Capital Minority
Gimv PE/Buyout Minority
You’re viewing 5 of 11 investors. Get the full list »

Precirix FAQs

  • When was Precirix founded?

    Precirix was founded in 2014.

  • Where is Precirix headquartered?

    Precirix is headquartered in Brussels, Belgium.

  • What is the size of Precirix?

    Precirix has 43 total employees.

  • What industry is Precirix in?

    Precirix’s primary industry is Biotechnology.

  • Is Precirix a private or public company?

    Precirix is a Private company.

  • What is the current valuation of Precirix?

    The current valuation of Precirix is .

  • What is Precirix’s current revenue?

    The current revenue for Precirix is .

  • How much funding has Precirix raised over time?

    Precirix has raised $133M.

  • Who are Precirix’s investors?

    Forbion, Inkef, Jeito, BioMedPartners, and Gimv are 5 of 11 investors who have invested in Precirix.

  • Who are Precirix’s competitors?

    Kite Pharma, Genprex, Light Chain Bioscience, Loxo Oncology, and Aileron Therapeutics are some of the 33 competitors of Precirix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »